Allogene Therapeutics Inc is at the forefront of developing innovative cancer treatments. Focused on immuno-oncology, this company is working on creating genetically engineered allogeneic T cell therapies. Its pipeline includes promising candidates like UCART19 for B-cell ALL and ALLO-501 for non-Hodgkin lymphoma, among others targeting various cancers. With strategic collaborations, including with Pfizer and The University of Texas MD Anderson Cancer Center, Allogene aims to revolutionize cancer treatment. Founded in 2017, its headquarters are in South San Francisco, California.
A single analyst note sent Kyverna Therapeutics tumbling despite a clinical milestone that had investors cheering just weeks ago, and the question now is whether the selloff marks a buying opportunity or…
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth. Five therapeutic categories are absorbing most strategic capital: radiopharmaceuticals, next-gen GLP-1,…
Penny stocks are some of my favorite stocks to watch. When these young budding companies release news, their stock prices can make tremendous moves. Of course, if the news is positive, those…
With the earnings season winding down and windows for making insider purchases opening up, insiders have been scooping up shares of these six stocks.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
Monday's top analyst upgrades and downgrades included Accenture, Analog Devices, Baxter International, Best Buy, Coinbase Global, Johnson Controls, Lam Research, Micron Technology and Qualcomm.
Thursday's top analyst upgrades and downgrades included AppLovin, Carvana, CrowdStrike, DocuSign, Fisker, Foot Locker, Intuitive Surgical, Rivian Automotive, Shopify, UnitedHealth, Workday and XPO Logistics.
Friday's additional top analyst upgrades and downgrades included Allogene Therapeutics, CSX, Norfolk Southern, Qualcomm, Toyota and Yelp.
One of Cathie Wood's ARK Invest exchange-traded funds bought over 1.5 million shares of Allogene on December 14.
Friday's top analyst upgrades and downgrades included Caesars Entertainment, Charter Communications, Conagra Brands, Corning, Denny’s, General Electric, Home Depot, Plug Power, Sirius XM, 3M and Union Pacific.
Monday’s top analyst upgrades and downgrades included Accenture, Arcturus, Elastic, Marathon, Riot Blockchain, ResMed, Sykes Enterprises, Western Alliance Bancorp and more.
